LT3254681T - N-(5s,6s,9r)-5-amino-6-(2,3-difluorfenil)-6,7,8,9-tetrahidro-5h-ciklohepta[b]piridin-9-il-4-(2-okso-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidin-1-karboksilato druska - Google Patents

N-(5s,6s,9r)-5-amino-6-(2,3-difluorfenil)-6,7,8,9-tetrahidro-5h-ciklohepta[b]piridin-9-il-4-(2-okso-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidin-1-karboksilato druska

Info

Publication number
LT3254681T
LT3254681T LTEP17180587.2T LT17180587T LT3254681T LT 3254681 T LT3254681 T LT 3254681T LT 17180587 T LT17180587 T LT 17180587T LT 3254681 T LT3254681 T LT 3254681T
Authority
LT
Lithuania
Prior art keywords
pyridin
cyclohepta
imidazo
difluorophenyl
tetrahydro
Prior art date
Application number
LTEP17180587.2T
Other languages
English (en)
Inventor
Daniel Richard Roberts
Richard Raymond Schartman
Chenkou Wei
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47844498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3254681(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of LT3254681T publication Critical patent/LT3254681T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LTEP17180587.2T 2012-02-27 2013-02-25 N-(5s,6s,9r)-5-amino-6-(2,3-difluorfenil)-6,7,8,9-tetrahidro-5h-ciklohepta[b]piridin-9-il-4-(2-okso-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidin-1-karboksilato druska LT3254681T (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261603598P 2012-02-27 2012-02-27

Publications (1)

Publication Number Publication Date
LT3254681T true LT3254681T (lt) 2019-09-25

Family

ID=47844498

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP17180587.2T LT3254681T (lt) 2012-02-27 2013-02-25 N-(5s,6s,9r)-5-amino-6-(2,3-difluorfenil)-6,7,8,9-tetrahidro-5h-ciklohepta[b]piridin-9-il-4-(2-okso-2,3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidin-1-karboksilato druska
LTEP13708603.9T LT2820016T (lt) 2012-02-27 2013-02-25 N-(5s, 6s, 9r)-5-amino-6-(2, 3-difluorfenil) -6,7,8, 9-tetrahidro-5h-ciklohepta[b]piridin-9-il- 4-(2-okso-2, 3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidin-1-karboksilatas, hemisulfato druska

Family Applications After (1)

Application Number Title Priority Date Filing Date
LTEP13708603.9T LT2820016T (lt) 2012-02-27 2013-02-25 N-(5s, 6s, 9r)-5-amino-6-(2, 3-difluorfenil) -6,7,8, 9-tetrahidro-5h-ciklohepta[b]piridin-9-il- 4-(2-okso-2, 3-dihidro-1h-imidazo[4,5-b]piridin-1-il)piperidin-1-karboksilatas, hemisulfato druska

Country Status (25)

Country Link
US (1) US8759372B2 (lt)
EP (2) EP2820016B1 (lt)
JP (2) JP6208154B2 (lt)
KR (2) KR102220969B1 (lt)
CN (1) CN104136437B (lt)
AU (1) AU2013226361B2 (lt)
BR (1) BR112014021032B1 (lt)
CA (1) CA2865585C (lt)
CY (2) CY1119448T1 (lt)
DK (2) DK2820016T3 (lt)
EA (1) EA025358B1 (lt)
ES (2) ES2642737T3 (lt)
HK (1) HK1248111B (lt)
HR (2) HRP20171620T1 (lt)
HU (2) HUE047050T2 (lt)
IL (1) IL234272B (lt)
LT (2) LT3254681T (lt)
MX (1) MX352171B (lt)
NO (1) NO2935439T3 (lt)
PL (2) PL3254681T3 (lt)
PT (2) PT2820016T (lt)
RS (2) RS59295B1 (lt)
SG (1) SG11201404834XA (lt)
SI (2) SI2820016T1 (lt)
WO (1) WO2013130402A1 (lt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2861392C (en) 2012-01-26 2021-08-17 Christopher J. Soares Peptide antagonists of the calcitonin cgrp family of peptide hormones and their use
EA025358B1 (ru) * 2012-02-27 2016-12-30 Бристол-Майерс Сквибб Компани N-(5S,6S,9R)-5-АМИНО-6-(2,3-ДИФТОРФЕНИЛ)-6,7,8,9-ТЕТРАГИДРО-5H-ЦИКЛОГЕПТА[b]ПИРИДИН-9-ИЛ-4-(2-ОКСО-2,3-ДИГИДРО-1H-ИМИДАЗО[4,5-b]ПИРИДИН-1-ИЛ)ПИПЕРИДИН-1-КАРБОКСИЛАТНАЯ СОЛЬ
EP2815749A1 (en) 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
RU2764767C2 (ru) 2015-03-06 2022-01-21 Атеа Фармасьютикалс, Инк. β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-С-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ
ES2965087T3 (es) * 2016-09-02 2024-04-10 Soares Christopher J Uso de antagonistas de receptor de CGRP en el tratamiento de glaucoma
PL3512863T3 (pl) 2016-09-07 2022-04-04 Atea Pharmaceuticals, Inc. 2'-Podstawione-N6-podstawione nukleotydy purynowe do leczenia zakażeń wirusem RNA
SG10202012214WA (en) * 2017-02-01 2021-01-28 Atea Pharmaceuticals Inc Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
SG11202009199YA (en) * 2018-03-25 2020-10-29 Biohaven Pharm Holding Co Ltd Rimegepant for cgrp related disorders
WO2019200005A1 (en) 2018-04-10 2019-10-17 Atea Pharmaceuticals, Inc. Treatment of hcv infected patients with cirrhosis
MX2021008191A (es) * 2019-01-20 2021-08-11 Biohaven Pharm Holding Co Ltd Antagonistas del péptido relacionado con el gen de calcitonina (cgrp) para el tratamiento de la irrupción de migraña.
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
EP4301362A1 (en) 2021-03-02 2024-01-10 CGRP Diagnostics GmbH Treatment and/or reduction of occurrence of migraine
WO2023026205A1 (en) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Preventative treatment of migraine
AR126954A1 (es) * 2021-09-02 2023-12-06 Biohaven Pharm Holding Co Ltd Métodos para tratar la psoriasis con uno o más antagonistas de receptores de cgrp
CN115850266A (zh) * 2021-09-26 2023-03-28 奥锐特药业(天津)有限公司 瑞美吉泮新晶型及其制备方法
CN116554164A (zh) * 2022-01-27 2023-08-08 奥锐特药业(天津)有限公司 一种瑞美吉泮的制备方法
WO2023175632A1 (en) * 2022-03-17 2023-09-21 Msn Laboratories Private Limited, R&D Center Solid state forms of (5s,6s,9r)-5-amino-6-(2,3difluorophenyl)-6,7,8,9-tetrahydro-5h-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-1-yl)-1-piperidinecarboxylate hemisulfate and processes for preparation thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA24500A1 (fr) * 1997-03-21 1998-10-01 Lg Life Sciences Ltd Derive du sel d'acide carboxylique de naphthyridine .
JO2355B1 (en) 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
CN1930145B (zh) 2004-03-05 2011-06-15 Msdk.K.公司 环烷吡啶衍生物
EP1802637B1 (en) 2004-10-13 2008-10-15 Merck & Co., Inc. Cgrp receptor antagonists
EP1804919B1 (en) 2004-10-22 2011-03-30 Merck Sharp & Dohme Corp. Cgrp receptor antagonists
EP2007763A2 (en) 2006-04-10 2008-12-31 Merck & Co., Inc. Process for the preparation of pyridine heterocycle cgrp antagonist intermediate
DE102006017827A1 (de) * 2006-04-13 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue kristalline Verbindungen
US8143403B2 (en) 2008-04-11 2012-03-27 Bristol-Myers Squibb Company CGRP receptor antagonists
US8044043B2 (en) 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
US8314117B2 (en) * 2009-10-14 2012-11-20 Bristol-Myers Squibb Company CGRP receptor antagonists
US8669368B2 (en) 2010-10-12 2014-03-11 Bristol-Myers Squibb Company Process for the preparation of cycloheptapyridine CGRP receptor antagonists
US8748429B2 (en) 2011-04-12 2014-06-10 Bristol-Myers Squibb Company CGRP receptor antagonists
EA025358B1 (ru) * 2012-02-27 2016-12-30 Бристол-Майерс Сквибб Компани N-(5S,6S,9R)-5-АМИНО-6-(2,3-ДИФТОРФЕНИЛ)-6,7,8,9-ТЕТРАГИДРО-5H-ЦИКЛОГЕПТА[b]ПИРИДИН-9-ИЛ-4-(2-ОКСО-2,3-ДИГИДРО-1H-ИМИДАЗО[4,5-b]ПИРИДИН-1-ИЛ)ПИПЕРИДИН-1-КАРБОКСИЛАТНАЯ СОЛЬ

Also Published As

Publication number Publication date
CY1119448T1 (el) 2018-03-07
IL234272B (en) 2018-10-31
EP3254681B1 (en) 2019-06-19
EP3254681A1 (en) 2017-12-13
BR112014021032B1 (pt) 2022-09-27
EP2820016A1 (en) 2015-01-07
JP2015511581A (ja) 2015-04-20
NO2935439T3 (lt) 2018-03-31
LT2820016T (lt) 2017-10-25
RS59295B1 (sr) 2019-10-31
AU2013226361B2 (en) 2017-09-21
DK3254681T3 (da) 2019-09-30
JP6208154B2 (ja) 2017-10-04
RS56556B1 (sr) 2018-02-28
ES2642737T3 (es) 2017-11-17
MX352171B (es) 2017-11-13
PT3254681T (pt) 2019-10-01
PT2820016T (pt) 2017-10-18
EP2820016B1 (en) 2017-08-02
US8759372B2 (en) 2014-06-24
WO2013130402A1 (en) 2013-09-06
CA2865585C (en) 2019-12-10
CA2865585A1 (en) 2013-09-06
CN104136437B (zh) 2016-05-11
KR102076118B1 (ko) 2020-02-11
KR102220969B1 (ko) 2021-02-25
CN104136437A (zh) 2014-11-05
BR112014021032A2 (lt) 2017-06-20
EA201491585A1 (ru) 2015-01-30
PL3254681T3 (pl) 2019-12-31
KR20200016993A (ko) 2020-02-17
ES2746031T3 (es) 2020-03-04
HRP20171620T1 (hr) 2017-12-01
HUE034936T2 (hu) 2018-03-28
HK1248111B (zh) 2020-04-17
HRP20191655T1 (hr) 2019-12-13
JP6476253B2 (ja) 2019-02-27
SG11201404834XA (en) 2014-09-26
JP2017226693A (ja) 2017-12-28
US20130225636A1 (en) 2013-08-29
KR20140130140A (ko) 2014-11-07
SI3254681T1 (sl) 2019-10-30
HUE047050T2 (hu) 2020-04-28
MX2014009544A (es) 2014-11-10
PL2820016T3 (pl) 2018-01-31
AU2013226361A1 (en) 2014-10-16
DK2820016T3 (da) 2017-11-13
EA025358B1 (ru) 2016-12-30
SI2820016T1 (sl) 2017-11-30
CY1122121T1 (el) 2020-11-25

Similar Documents

Publication Publication Date Title
HK1248111B (zh) N-(5s，6s，9r)-4-(2-氧代-2，3-二氫-1h-咪唑並[4，5-b]吡啶-1-基)呱啶-1-羧酸5-氨基-6-(2，3-二氟苯基)-6，7，8，9-四氫-5h-環庚三烯並[b]吡啶-9-基酯半硫酸鹽
ZA201906379B (en) 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
HK1217488A1 (zh) -二氨基- -氟苄基 -吡唑并 吡啶- -基 嘧啶- -基}甲基氨基甲酸甲酯的形式
EP2931722A4 (en) SUBSTITUTED 1H-PYRROLO- [2,3-B] PYRIDINE AND 1H-PYRAZOLO- [3,4-B] PYRIDINE DERIVATIVES AS SALT-INDUCIBLE KINASE-2 (SIK2) INHIBITORS
HK1210472A1 (en) Spirocyclic derivatives as antiparasitic agents
ZA201209632B (en) Imidazopyridine derivatives, process for the preparation thereof and therapeutic use thereof
ZA201409299B (en) Risperidone or paliperidone implant formulation
PT2609082E (pt) Imidazo[4,5-c]quinolinas como inibidores de dna-pk
IL232906A (en) Pyrazolopyridine derivatives, a process for their preparation and medical use
ZA201405070B (en) 1h-pyrrolo[2,3-b] pyridine derivatives and their use as kinase inhibitors